Université Libre de Bruxelles-ko ikertzaileekin lankidetzan egindako argitalpenak (14)

2024

  1. Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)

    Radiotherapy and Oncology

  2. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations

    The Lancet Oncology, Vol. 25, Núm. 2, pp. e73-e83

2023

  1. Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer

    European Journal of Cancer, Vol. 178, pp. 23-33

  2. Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2998-3008

  3. Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2988-2997

  4. Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis

    Radiotherapy and Oncology, Vol. 186

2022

  1. Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis

    npj Breast Cancer, Vol. 8, Núm. 1

2021

  1. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer ☆

    Annals of Oncology, Vol. 32, Núm. 12, pp. 1475-1495

  2. Sacituzumab govitecan in metastatic triple-negative breast cancer

    New England Journal of Medicine, Vol. 384, Núm. 16, pp. 1529-1541

2020

  1. Beta-blocker effect on ST-segment: A prespecified analysis of the EARLY-BAMI randomised trial

    Open Heart, Vol. 7, Núm. 2

  2. ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer

    ESMO Open, Vol. 5

  3. Oncological care organisation during COVID-19 outbreak

    ESMO Open, Vol. 5, Núm. 4

  4. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy

    British Journal of Cancer

2016

  1. Handbook of HER2-targeted agents in breast cancer

    Springer International Publishing, pp. 1-110